The NCMAG Council makes decisions on the proposed use of cancer medicines.
These medicines uses are planned for review by NCMAG:
NCMAG 129 Aspirin
Adjuvant treatment of patients with resected stage I to III rectal cancer or stage II to III colon cancer and PI3K pathway alterations (off-label and off-patent medicine).
- Council meeting date: 17 September 2026
- Planned publication date: 22 October 2026
NCMAG 130 Aspirin
For cancer prevention in people with Lynch syndrome (off-label and off-patent medicine).
- Council meeting date: 10 December 2026
- Planned publication date: 14 January 2027
NCMAG 131 Pemigatinib
For the first line treatment of locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement in frail adults not fit for chemotherapy-based treatment (off-label and on-patent medicine).
- Council meeting date: 17 September 2026
- Planned publication date: 14 January 2027